Loading
A phase 3 trial of Daromun in melanoma, run by Philogen S.p.A., now recruiting.
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients is a phase 3 interventional study registered as NCT03567889 by Philogen S.p.A., with 186 participants planned, started 2018-09-20 and due to reach its primary completion in 2027-12. Interventions recorded: Daromun, Surgery and Adjuvant therapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Philogen S.p.A., Stage III melanoma (after surgery), Melanoma and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Stage III melanoma (after surgery), Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/